Ipv Infanrix (Pertussis Filamentous Haemagglutinin Adsorbed On Aluminium Hydroxide, Hydrated, Pertussis Toxoid Ads)

• Ipv Infanrix is a pertussis vaccine that targets the bacterial pathogen responsible for whooping cough, forming part of routine immunisation programmes.
• Pertussis (whooping cough): Provides active immunity to prevent infection in infants and young children.
• Infants: Reduces the risk of severe pertussis disease during the first months of life.
• Children: Supports long‑term protection against pertussis as part of routine immunisation schedules.
• Adolescents: Boosts waning immunity and helps maintain herd protection.
• Adults: Provides booster immunity to maintain protection against pertussis.

• The vaccine contains purified pertussis filamentous haemagglutinin and pertussis toxoid adsorbed onto aluminium hydroxide, an adjuvant that enhances antigen presentation. After intramuscular injection, the antigens are taken up by antigen‑presenting cells, stimulating B‑cell and T‑cell responses that generate specific antibodies and memory cells, thereby establishing active immunity against Bordetella pertussis.

Ipv Infanrix may be associated with local and systemic reactions typical of injectable vaccines.

Common Side Effects

• Pain at the injection site: mild to moderate discomfort.
• Redness or swelling: localized inflammation.
• Low‑grade fever: transient rise in body temperature.
• Irritability or fussiness: especially in infants.
• Reduced appetite: temporary decrease in feeding.
• Mild headache: occasional in older recipients.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Seizures: febrile or non‑febrile convulsions.
• High fever: temperature above 40 °C.
• Prolonged crying: lasting more than three hours.
• Severe allergic rash: widespread hives or angioedema.
• Encephalopathy: very rare neurologic complication.

• Prior to administration, clinicians should assess individual risk factors and follow recommended handling procedures.
• Screen for severe allergy: Verify no known hypersensitivity to any vaccine component.
• Delay vaccination: Postpone if a moderate or severe acute illness is present.
• Avoid concurrent live vaccines: Separate administration by at least four weeks.
• Monitor infants: Observe for fever or unusual behavior after injection.
• Pregnancy: Use only if benefits outweigh risks, per clinician judgment.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccination may interact with other therapies that affect the immune system or antigen exposure.

Major Interactions (Avoid)

• Concurrent administration with blood products: May reduce immune response.
• Live bacterial vaccines given within four weeks: Potential interference with immune response.
• Immunoglobulin therapy within two weeks: May blunt vaccine efficacy.

Moderate Interactions (Monitor Closely)

• Concurrent administration of other inactivated vaccines: Generally safe but monitor for increased reactogenicity.
• Use of immunosuppressive therapy: May diminish antibody response, consider timing.
• Concurrent antipyretics: May mask fever, monitor temperature.